Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.45 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619669 | 0.85 | HCAR2 (0.54) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL6371053 | 0.80 | HCAR2 (0.57) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5600122 | 0.79 | HCAR2 (0.55) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL28860793 | 0.77 | HCAR2 (0.53) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599995 | 0.75 | HCAR2 (0.51) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL2360520 | 0.73 | HCAR2 (0.52) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL24990859 | 0.72 | COMT (0.48) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599968 | 0.72 | HCAR2 (0.49) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5600084 | 0.71 | HCAR2 (0.47) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL220072 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | claimed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | HCAR2 52/4885DAO 2261/4885HCAR3 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.